Form 4: Director Nancy Andrews Receives Stock Options in Maze

Director Nancy C. Andrews was granted 18,000 stock options in Maze Therapeutics, Inc. as part of a standard equity incentive.

Summary

• Nancy C. Andrews, a Director at Maze Therapeutics, Inc., was granted 18,000 stock options.
• The options have an exercise price of $23.58 per share.
• The grant date for the transaction was June 8, 2026.
• The options are scheduled to vest on the earlier of the 2027 annual stockholders meeting or June 8, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's operational outlook.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in potential future dilution of existing shareholders upon exercise of the options.

Risks

• Vesting is contingent upon the reporting person's continued service to the issuer.

Future Outlook

The options vest in one year, contingent on continued service, reflecting a standard retention and incentive structure for board members.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to ensure board alignment with corporate milestones and long-term valuation.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.

Stakeholder Impact

• Minor dilution impact for existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on or before June 8, 2027.

Key Dates

Keywords

Maze Therapeutics, MAZE, Form 4, Insider Trading, Stock Options, Director Compensation